台灣外科醫學會雜誌

中文 | ENG

	第58卷第3期 2025-5 Elevating the standards of scientific editing in clinical surgery: Learning from editorial and journal role models
.........................
	第58卷第3期 2025-5 Improving online physician evaluations for surgeons using sentiment analysis and alternative perspectives
.........................
	第58卷第3期 2025-5 Ensuring ethical and qualified authorship: The key to trustworthiness in clinical surgery journal
.........................
	第58卷第3期 2025-5 Artificial intelligence for academic purpose in clinic surgery: ChatGPT, Turnitin, and false positive
.........................
	第58卷第3期 2025-5 COVID-19, COVID-19 vaccination, risk of cardiac myxoma in view of clinical surgery
.........................
	第58卷第3期 2025-5 Eggplant deformity in penile fracture
.........................
	第58卷第3期 2025-5 Splenectomy for Klippel-Trenaunay syndrome: Systematic review and case series
.........................
	第58卷第3期 2025-5 Comments on “Risk factors for spinal cord injury without radiographic abnormality in trauma cases at a single trauma center”
.........................
	第58卷第3期 2025-5 Impact of fluorescence-guided surgery on splenic preservation: A case of splenic hydatidosis
.........................
	第58卷第3期 2025-5 Adult pancreatoblastoma presentingwith obstructive jaundice: A case report and literature review
.........................
	第58卷第3期 2025-5 Pilonidal disease management in young adults: A retrospective analysis of practices in a single tertiary center in Bahrain
.........................
	第58卷第3期 2025-5 Long-term comparative outcomes in patients undergoing transcatheter aortic valve implantation with self-expanding valves versus balloon-expandable valves: A retrospective observational study
.........................
	第58卷第3期 2025-5 Comparative study between the effectiveness of Amnion-CollaGee (Collagen-Gelatin-Elastin) as a biological product wound dressing and conventional dressing on the donor site of the split-thickness skin graft in animals model (rats)
.........................
	第58卷第3期 2025-5 Enhancing mortality Probability Model II predictive accuracy with the lethal triad in intensive care unit trauma patients: A retrospective study
.........................
	第58卷第3期 2025-5 Dr. Shao-Wei Chen's contribution to analysis of outcomes of patients undergoing cardiac surgery and aortic disease: Big data analytics
.........................
	第58卷第2期 2025-3 Predatory publisher and low standard journal: An emerging problem in clinical surgery field
.........................
	第58卷第2期 2025-3 Conflict of interest in clinical surgery: Contemporary concern in digital era
.........................
	第58卷第2期 2025-3 Postpublication redecision and pitfalls of inadequate standards in scientific surgical journals: Important consideration in academic publication
.........................
	第58卷第2期 2025-3 Spontaneous bilateral basal ganglia hemorrhage
.........................
	第58卷第2期 2025-3 Academic characterization of the Formosan Journal of Surgery: A five-year bibliometric analysis
.........................

登入帳號才能閱讀全文

篇名	Purification and characterization of type AI arginase with immune inhibitory activity: Potential for the treatment of transplant rejection
作者	Soo-Ray Wang
卷期/出版年月	35卷2期 (2002/4)
頁次	59-66
摘要	A protein obtained from mammalian livers capable of inhibiting mitogen-induced lymphocyte proliferation, is called “liver-derived inhibitory protein”, or has been purified from mouse ;over homogenates and was proven to be arginase. Arginase in mammalian body has two isoforms, type I is liver orgin (i.e. LIP), type II exists in other tissues of the body. LIP can inhibit boyh Y- and B-lymphocytes. It is temperature stable up to 65℃ and PH stable from 3 to 11. LIP molecular weight is 105 kDa. The immune inhibitory property of liver arginase is due to arginine depletion resulting in suppression of syntheses of thymidine kinase and uridine kinase which have a half of only two hours; hence the DNA and RNA syntheses are inhibited and cell proliferation is suppressed. Liver arginase is the only mammalian amino acid-degradation enzyme that can potently inhibit lymphocyte proliferation. Because lymphocyte inhibition by liver arginase is reversible and is of non-cytotoxic, it is conceivable that liver arginase of human origin has a great potential of therapeutical benefit in treating transplant rejection.
關鍵詞
分類	Overview